Viral Conjunctivitis Drugs Market, by Drug Class (Artificial tears, Decongestants, Anti-histaminic, NSAIDS, and Anti-Viral), by Distribution Channel (Hospital Pharmacy and Retail Pharmacy), and by Geography - Global Industry Insights, Trends, Outlook and Opportunity Analysis 2018-2026

  • To Be Published : Jun 2019 |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Viral conjunctivitis is an inflammation of the conjunctiva, which is a thin outermost layer of the sclera and inner layer of eyelid. Viral conjunctiva is caused due to infections from virus such as adenovirus, herpes simplex virus, varicella zoster virus, picornavirus, poxvirus, and human immunodeficiency virus. It is also called as Pinkeye disease. Viral conjunctivitis is characterized by the reddish eye, watery discharge from eye, and itching/irritation. Persistent conjunctivitis from virus may lead to corneal keratitis. Treatment for viral conjunctivitis may be symptomatic or virus specific.

Treatment can include artificial tear drops to lower the dryness and irritation from infection, vasoconstrictors to reduce eye redness, decongestants to reduce the swelling, and antihistamines to reduce itching. Treatments usually are continued for one to two weeks, depending on the severity of the infection. Anti-viral therapy is utilized to treat infections from herpes simplex and varicella zoster virus.

New drugs development in the U.S. to propel growth of the viral conjunctivitis market

According to study published in the journal Ophthalmology in December 2017, approximately 80% of conjunctivitis cases in the U.S. are associated with viral conjunctivitis. According to study published in Review of Ophthalmology in January 2017, around 15 per 1000 population in the U.S. suffer from viral conjunctivitis. As per a study in Review of Optometry in 2016, an estimated 20,000 new cases, 48,000 cases of recurrences, and prevalence of 4,00,000 cases of herpes simplex keratitis were reported every year in U.S. Considering this facts, U.S. is expected to dominate the viral conjunctivitis drugs market. Also, increasing investment for development of new drugs to treat the viral conjunctivitis are further expected to propel the viral conjunctivitis drugs market growth. For instance, APD-209 is a drug candidate from Adenovir Pharma AB to treat epidemic keratoconjunctivitis from adenovirus, which has completed the phase 2 clinical studies in 2016. There is also increased awareness amongst patients about approaching the ophthalmologist to treat viral conjunctivitis.

However, there is no direct anti-viral treatment available yet for conjunctivitis, which if available may open new opportunity in viral conjunctivitis drugs market. To treat viral conjunctivitis often it becomes difficult to clinically differentiate the viral conjunctivitis from the bacterial conjunctivitis which leads to miss diagnosis. Many physicians at primary care centers prescribe antibiotic to treat viral conjunctivitis due to miss diagnosis and this chain of events limits the expansion of viral conjunctivitis drugs market. According to 2017 study in Ophthalmology, an estimated 83% patients of acute conjunctivitis visited primary care centers instead of ophthalmologist, which leads to overlap of diagnosis and treatment of viral conjunctivitis in turn restraining market growth.

Viral Conjunctivitis Drugs Market Taxonomy

On the basis of drug class:

  • Artificial tears
  • Decongestants
  • Anti-histaminic
  • Anti-Viral drugs

On the basis of the distribution channel:

  • Hospital Pharmacy
  • Retail Pharmacy

Key players operating in the viral conjunctivitis drugs market include Bausch & Lomb, Allergan plc, Shire plc, NicOx S.A, NovaBay Pharmaceuticals, Inc., NanoViricides, Inc., Novartis International AG, Adenovir Pharma AB, Panoptes Pharma GES.M.B.H., Akorn Pharmaceuticals, and Quidel Corporation. Market players are investing in research to development of novel therapies to treat viral conjunctivitis.

NiCox S.A. in March 2017, received the FDA approval for its ZERVIATE1 (cetirizine ophthalmic solution 0.24%) as New Drug Application (NDA), which is the first antihistaminic topical ocular formulation for the treatment of itching due to allergic conjunctivitis. Company is looking to commercialize the product in the U.S. through partnership. In 2015, Shire plc announced acquisition of Foresight Biotherapeutics for US$ 300 million. Foresight Biotherapeutics has experimental eye drop FST-100 in its pipeline, which is a combination of 0.6% povidone iodine and 0.1% dexamethasone to treat both viral and bacterial conjunctivitis. This acquisition would add growth to Shire plc’s ophthalmic portfolio.

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.

Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.
Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.